People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare.
J Intern Med
; 295(3): 281-291, 2024 Mar.
Article
de En
| MEDLINE
| ID: mdl-38098165
ABSTRACT
The development of disease-modifying therapies (DMTs) for Alzheimer's disease (AD) has progressed over the last decade, and the first-ever therapies with potential to slow the progression of disease are approved in the United States. AD DMTs could provide life-changing opportunities for people living with this disease, as well as for their caregivers. They could also ease some of the immense societal and economic burden of dementia. However, AD DMTs also come with major challenges due to the large unmet medical need, high prevalence of AD, new costs related to diagnosis, treatment and monitoring, and uncertainty in the therapies' actual clinical value. This perspective article discusses, from the broad perspective of various health systems and stakeholders, how we can overcome these challenges and improve society's readiness for AD DMTs. We propose that innovative payment models such as performance-based payments, in combination with learning healthcare systems, could be the way forward to enable timely patient access to treatments, improve accuracy of cost-effectiveness evaluations and overcome budgetary barriers. Other important considerations include the need for identification of key drivers of patient value, the relevance of different economic perspectives (i.e. healthcare vs. societal) and ethical questions in terms of treatment eligibility criteria.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Maladie d'Alzheimer
Limites:
Humans
Pays/Région comme sujet:
America do norte
Langue:
En
Journal:
J Intern Med
Sujet du journal:
MEDICINA INTERNA
Année:
2024
Type de document:
Article
Pays d'affiliation:
Suède
Pays de publication:
Royaume-Uni